logo-loader
viewReNeuron Group PLC

ReNeuron's Michael Hunt updates on product development

Michael Hunt, CFO at ReNeuron Group Plc (LON:RENE) chats to Proactive to update on the cell-based therapeutics specialist's research and development programmes.

Hunt says they're to increase the number of clinical sites in their PISCES III study from 25 to 40.

PISCES III is a phase IIb clinical study in the US of ReNeuron’s CTX cell therapy candidate for stroke disability.

First patient dosing in the study is expected in mid-2018 and top-line data from the study, as previously indicated, is expected in late 2019.

Quick facts: ReNeuron Group PLC

Price: 141.5 GBX

LSE:RENE
Market: LSE
Market Cap: £45.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18

2 min read